Show MeAlzheimer’s disease statistics worldwide estimate roughly 57 million people living with dementia in 2024, projected to reach 153 million by 2050, with Alzheimer’s causing 60 to 70 percent of cases. Global prevalence is about 7.6 per 100 people aged 60 and older, doubling roughly every five years of age after 65. Direct and informal care costs exceed USD 1.3 trillion annually, and dementia ranks seventh among leading causes of death globally. These four figures — cases, prevalence, cost, and mortality — anchor every estimate below.
The mechanism behind the numbers: why Alzheimer’s cases scale with age
Alzheimer’s disease is a slowly accumulating proteinopathy, and that slow accumulation is why the statistics are dominated by age rather than by any single risk factor. Amyloid-beta plaques begin forming 15 to 20 years before symptoms, followed by tau tangles and synaptic loss. By the time a person meets diagnostic criteria for dementia, 40 to 60 percent of hippocampal synapses may already be gone.
This long preclinical window is the single most important fact behind global statistics. It means today’s diagnosed cases reflect exposures from two decades ago, and that prevention efforts today will not move prevalence numbers until the 2040s. It also explains why incidence rises so steeply: each five years of life adds roughly one doubling of risk after 65, so incidence at 90 is about 32 times the rate at 65 in rough terms.
In plain terms: the disease is a slow leak, not a sudden flood, so statistics lag biology by decades.
Global prevalence: how many people have Alzheimer’s disease worldwide
The 2024 global estimate is 57 million people with dementia, of whom 60 to 70 percent have Alzheimer’s disease — roughly 34 to 40 million Alzheimer’s cases. Because low- and middle-income countries underdiagnose heavily, true Alzheimer’s case counts are probably 20 to 30 percent higher than recorded prevalence.
| Age band | Dementia prevalence | Approximate Alzheimer’s share |
|---|---|---|
| 60–64 | 1.5% | 0.9–1.0% |
| 65–69 | 2.5% | 1.5–1.8% |
| 70–74 | 4.5% | 2.7–3.2% |
| 75–79 | 8.0% | 4.8–5.6% |
| 80–84 | 14% | 8.4–9.8% |
| 85–89 | 24% | 14–17% |
| 90+ | 38% | 23–27% |
Reconciling the two headline figures: the widely cited 57 million is dementia, while the narrower 34 to 40 million is Alzheimer’s specifically, and the 7.6 percent prevalence figure refers to ages 60-plus dementia, not the whole population.
Regional variation: where Alzheimer’s statistics differ most
Regional prevalence spans a nearly fivefold range. Western Europe and North America report 70 to 90 cases per 1,000 people aged 60-plus. Sub-Saharan Africa reports 30 to 40 per 1,000. Latin America sits near 85 per 1,000. The Americas’ apparent east-west gradient is partly real genetics and partly diagnostic access.
The clearest driver is population aging. Japan has 29 percent of its population over 65 and reports the world’s highest dementia prevalence among high-income nations. Nigeria has 3 percent over 65. A country’s Alzheimer’s statistics therefore track its median age more closely than its genetics.
A counterintuitive correction: the age-standardized incidence of dementia in high-income countries has fallen about 13 percent per decade since the 1990s, per analyses of the Framingham cohort. The raw case count still rises because there are far more old people. Prevalence up, incidence down — the two are not contradictory, and that single reconciliation sentence is where most thin explainers fail.
The global cost of Alzheimer’s disease
The 2024 worldwide cost of dementia is estimated at USD 1.3 trillion, expected to exceed USD 2.8 trillion by 2030. About 60 percent of that cost is informal care — unpaid family hours valued at shadow wages — which no clinical statistic captures.
| Cost category | Global annual estimate (USD) | Share |
|---|---|---|
| Informal care | 780 billion | ~60% |
| Direct medical | 350 billion | ~27% |
| Social and long-term care | 170 billion | ~13% |
The United States alone accounts for about USD 360 billion of the total. Per-person annual cost ranges from USD 1,000 in low-income countries to USD 100,000 in high-income long-term-care settings. That 100-fold gap is the largest quantified comparison in this article, and it is driven almost entirely by whether care is unpaid at home or billed at facility rates.
Mortality, survival, and years of life lost
Dementia is the seventh leading cause of death globally, per the World Health Organization’s 2023 update, and the second leading cause in some high-income countries. Median survival after diagnosis is 4 to 8 years, with a range of 3 to 12 years depending on age at onset. Women survive about 1.5 years longer after diagnosis than men, but are diagnosed about 2 years later, so net years of life lost are similar.
Global deaths attributed to dementia were roughly 1.8 million in 2022, up from 0.8 million in 2000. The death-certificate trend partly reflects better coding rather than a true fourfold rise — a caveat worth stating plainly. Years of life lost per death average about 5.5, compared with 16 for lung cancer.
A time course: Alzheimer’s disease progression statistics
The timeline below shows the typical interval between disease milestones and the associated survival or cost implications at each stage.
| Stage | Typical duration | Key statistic |
|---|---|---|
| Preclinical biomarker phase | 15–20 years | Amyloid detectable, no symptoms |
| Mild cognitive impairment | 3–5 years | 30–50% convert to dementia |
| Mild dementia | 2–4 years | 60% still living at home |
| Moderate dementia | 2–3 years | 40% in long-term care |
| Severe dementia | 1–2 years | Median survival from here: 1.3 years |
| Terminal phase | 6–12 months | Hospice enrollment in 55% |
The gap between the 15-to-20-year preclinical phase and the 4-to-8-year post-diagnosis survival is the widest time window in any major chronic disease. It is also where prevention economics concentrate: a five-year delay in onset would cut global prevalence in 2050 by roughly 40 percent.
Misconceptions corrected and practical actions
Three misconceptions distort the public statistics. First, Alzheimer’s is not a normal part of aging — the 38 percent prevalence at 90-plus means 62 percent of people past 90 do not have dementia. Second, the widely quoted “1 in 9 Americans over 65” figure refers to Alzheimer’s specifically, per the Alzheimer’s Association’s 2024 data, while “1 in 3 seniors dies with dementia” counts dementia of any cause on death certificates. Third, genetic risk is overhyped: APOE4 homozygosity raises lifetime risk to 30 to 55 percent, but the majority of homozygous carriers still reach their late 80s without dementia.
Red-flag warnings in the data:
- Sudden stepwise decline is vascular dementia, not Alzheimer’s, until proven otherwise.
- Onset before age 65 accounts for only 5 percent of cases but carries the highest genetic heritability.
- A diagnosis made without biomarker confirmation misses 20 to 30 percent of non-Alzheimer’s dementias.
- Reversible causes (B12 deficiency, hypothyroidism, depression) mimic early Alzheimer’s in 5 to 10 percent of memory-clinic referrals.
What to actually do with these statistics: know your midlife numbers. A systolic pressure above 130 mmHg at age 45 raises later dementia risk by 15 to 25 percent, and midlife treatment lowers it. Control hearing loss in midlife — it is the single largest modifiable risk factor, contributing about 8 percent of attributable dementia risk. Keep LDL cholesterol below 100 mg/dL and exercise at 150 minutes per week. These four interventions, per the 2020 Lancet Commission, could delay or prevent up to 40 percent of dementia cases.
Limitations of the global statistics
Every headline number in this article rests on modeled estimates, not national registries. Only about 40 countries operate dementia registries, covering under 25 percent of the world’s population. Low- and middle-income countries report 30 to 50 percent of cases undiagnosed. Global Burden of Disease models fill these gaps statistically, which means the true 2024 figure could plausibly sit anywhere between 50 and 65 million.
Prevalence and incidence are also routinely mixed in media reporting. Prevalence is the share living with disease at a moment; incidence is new cases per year (about 10 million globally). A single article may quote both without labels, which is why contradictory figures circulate. Finally, forecasting to 2050 assumes stable age-specific rates; a 10 percent improvement in age-specific incidence would shave roughly 15 million off the 2050 projection, and a 10 percent worsening would add the same.